Janus Henderson Group Ltd. filed Amendment No. 2 to its Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 674,347 shares of Assembly Biosciences, Inc. common stock as of September 30, 2026.

Key Highlights

  • Beneficial ownership: Janus Henderson Group Ltd. reported aggregate beneficial ownership of 674,347 shares of Assembly Biosciences common stock, including shares obtainable through exercise of warrants.
  • Percent of class: The 674,347 shares represent 3.3% of the outstanding class of common stock, according to the filing.
  • Voting and dispositive power: Janus Henderson reported 0 shares with sole voting or sole dispositive power, and 674,347 shares with shared voting power and shared dispositive power.
  • Event date: The date of the event requiring the filing was September 30, 2026.
  • No individual Managed Portfolio holds more than 5%: The filing states that none of the Managed Portfolios individually own more than five percent of Assembly Biosciences common stock.
  • Filing entity type: Janus Henderson Group Ltd. is organized in Jersey and filed as a parent holding company (Type: HC).

Janus Henderson's Disclosed Position in Assembly Biosciences as of September 30, 2026

According to the Schedule 13G Amendment No. 2 filed on November 16, 2026, Janus Henderson Group Ltd., organized in Jersey and headquartered at 201 Bishopsgate, EC2M 3AE, United Kingdom, disclosed that it may be deemed the beneficial owner of 674,347 shares of common stock of Assembly Biosciences, Inc. (NASDAQ:ASMB), whose principal executive offices are located at Two Tower Place, 7th Floor, South San Francisco, CA 94080. The filing identifies the CUSIP number for the shares as 045396207.

The filing explains that Janus Henderson Group Ltd. is the ultimate parent of multiple SEC-registered investment advisers and foreign equivalents, referred to collectively as the Asset Managers. These include entities such as Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, and several others listed in the filing. The Asset Managers exercise investment and voting discretion on behalf of client accounts described as Managed Portfolios. The filing states that "the Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights," while the Managed Portfolios themselves hold those rights.

All 674,347 shares are reported under shared voting power and shared dispositive power, with zero shares attributed to sole voting or sole dispositive power. The filing further notes that the beneficial ownership reported by Janus Henderson Group Ltd. does not include any securities that may be beneficially owned by its ultimate parent, Janus Henderson Group Holdings, LLC, or by that entity's direct or indirect owners, in accordance with SEC Release No. 34-39538. The statement was signed by Kristin Mariani, Head of North America Compliance, on November 16, 2026.

What Was Disclosed

Janus Henderson Group Ltd. filed Amendment No. 2 to Schedule 13G disclosing 674,347 shares, or 3.3%, of Assembly Biosciences common stock beneficially owned as of September 30, 2026, held through its network of Asset Managers on behalf of Managed Portfolios.